Stock Analiz

BioRestorative Therapies, Inc. BRTX

Managed Health Care · data as of November 13, 2026

$1.49Market cap $2M
Open the interactive analysis →

BioRestorative Therapies, Inc. (BRTX) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to March 31, 2026 it had revenue of $357870 and net income of -$11M, a net margin of -3089.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 36% a year, a 5-year average ROIC of -803%.

About BioRestorative Therapies

BioRestorative Therapies is listed in the US and classified in managed health care. Revenue went from $415996 in 2014 to $359700 in 2025, a decline of about 1.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 149% over three years (dilution for shareholders). It spends 2806% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.8
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-578.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-10.3%
Revenue growth (5 yrs, per year)36.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-24138.5%
ROIC (5-yr avg.)-802.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$357870$359700$401000$145800$119800$46000$77000$130000$111000$81000$36355
Net income-$11M-$14M-$9M-$10M-$13M-$44M-$11M-$15M-$13M-$9M-$9M
Free cash flow-$12M-$11M-$8M-$7M-$6M-$3M—-$7M-$5M-$4M-$5M
EPS (diluted)$-1.07$-1.58$-1.16$-2.47$-3.65$-37.30$-28.56$-2640.00$-6559.99$-6959.99$-8399.99
Net margin-3089.6%-3959.4%-2239.2%-7145.2%-11037.0%-96311.5%-14639.9%-11267.6%-11277.3%-11660.1%-23755.4%
ROIC—-3465.0%-107.0%-118.3%-141.5%-181.5%-62.8%————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $300.00, 20034% above the current price; targets range from $300.00 to $300.00; the consensus rating is “none”; expected EPS is $-13.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does BioRestorative Therapies pay a dividend?

Not currently.

Is BioRestorative Therapies a good stock to buy?

We do not give buy or sell advice. BioRestorative Therapies scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.